Ibogaine for Methadone Dependence: The Evidence

Methadone is a long-acting full agonist at the mu-opioid receptor, used since the 1960s to treat opioid use disorder. In the United States it can be dispensed for addiction only through federally regulated opioid treatment programmes (OTPs), usually with daily supervised dosing.

Two different things get conflated in this search:

• Physical dependence on methadone is expected and pharmacologically normal. Anyone taking a daily mu-opioid agonist develops it. Needing a dose to avoid withdrawal is not, by itself, addiction.
• Opioid use disorder (OUD) is a behavioural diagnosis defined by compulsive use, loss of control, and continued use despite harm. There is no separate ICD-10 code for methadone maintenance; patients are generally coded under F11.20 (opioid dependence, uncomplicated).

Who searches for this. Access to methadone in the US is narrow and its users are highly constrained. Krawczyk and colleagues (Health Affairs Scholar, 2023) report that fewer than 5% of an estimated 7.6 million Americans with OUD receive methadone, that only about 20% of US counties contain an OTP, and that methadone treatment grew just 39% between 2010 and 2019 while buprenorphine prescribing grew 222%.

The people who look for alternatives tend to be those stabilised for years who want to be medication-free, those who find daily clinic attendance incompatible with work or travel, those who have tried tapering and failed, and those whose dose has crept upward over time.

One pharmacological fact governs everything below: methadone's elimination half-life is long and unusually variable, reported across studies at roughly 8 to 59 hours. That property is what makes once-daily dosing possible — and what makes any ibogaine protocol slow, uncertain, and difficult to time.

Conventional addiction medicine has a strong evidence base here, and it deserves accurate representation rather than a strawman.

Staying on methadone is the best-evidenced option. The Cochrane review by Mattick and colleagues (2009) pooled 11 randomised trials with 1,969 participants and found methadone maintenance significantly better than non-pharmacological approaches at retaining people in treatment and suppressing heroin use (RR 0.66, 95% CI 0.56–0.78). Differences in criminal activity and mortality did not reach significance in those trials, which were individually small and underpowered for death as an endpoint.

Larger observational data close that gap. Santo and colleagues (JAMA Psychiatry, 2021) pooled 15 trials and 36 cohort studies covering more than 749,000 people. Opioid agonist treatment was associated with more than a 50% reduction in all-cause mortality, and all-cause mortality was roughly six times higher in the four weeks after stopping treatment (RR 6.01). That number is the single most important figure on this page.

Tapering works for a minority. Nosyk and colleagues (Addiction, 2012) analysed 25,545 completed methadone episodes in British Columbia. Among the 4,917 taper episodes meeting inclusion criteria, 13% achieved sustained success — reaching 5 mg/day or less with no treatment re-entry, opioid-related hospitalisation, or death over 18 months. Across all episodes that began a taper, the figure was 4.4%. Longer tapers did substantially better: 12–52 weeks carried 3.58 times the odds of success versus under 12 weeks, and tapers over a year 6.68 times. The authors concluded plainly that most people attempting to taper will not succeed.

The honest summary: methadone maintenance is very good at keeping people alive and stable, and poor at helping people who want to be off it. That gap is where interest in ibogaine for methadone dependence concentrates.

Ibogaine is a psychoactive indole alkaloid from the root bark of Tabernanthe iboga. The property that attracts research attention is a repeatedly reported one: a single dose appears to attenuate opioid withdrawal within roughly 24 to 48 hours rather than over weeks.

The mechanism is not established. What is known:

• Ibogaine is not a mu-opioid agonist. Laboratory work by Maillet, Alper and colleagues found ibogaine, its metabolite noribogaine, and the analogue 18-MC behaved as mu-opioid receptor antagonists, with functional Ke values from about 3 µM to 13 µM. Whatever relieves withdrawal, it is not agonist substitution
• It is a non-competitive antagonist at α3β4 nicotinic acetylcholine receptors, an NMDA channel blocker, and an inhibitor of serotonin and dopamine transport — a genuinely multi-target profile
• It is metabolised chiefly by CYP2D6 to noribogaine, which has a long half-life of its own
• Rodent work shows sustained upregulation of glial cell line-derived neurotrophic factor (GDNF) in dopaminergic circuits, the most commonly cited mechanistic hypothesis

A second hypothesis is specific to methadone: that ibogaine reduces opioid tolerance, allowing a maintained patient to hold at a much lower methadone dose rather than withdraw entirely. This is the premise the only completed randomised trial was designed to test.

Two honesty markers belong here. First, human pharmacokinetic work by Knuijver and colleagues (Journal of Psychopharmacology, 2024) found ibogaine clearance strongly determined by CYP2D6 genotype and, notably, that neither ibogaine nor noribogaine plasma concentrations correlated with withdrawal severity — a negative finding for simple dose-response reasoning. Second, none of the foundational preclinical work used methadone-maintained animals.

Unusually for ibogaine, this indication has a completed randomised controlled trial — a small one, whose full results have not yet reached the peer-reviewed literature.

The ICEERS/Reus trial (NCT04003948). A Phase 2, randomised, quadruple-masked study run by the International Center for Ethnobotanical Education, Research, and Service with Hospital Universitari Sant Joan de Reus enrolled 20 methadone-maintained participants in Catalonia between October 2020 and April 2024. One arm received fixed 100 mg ibogaine hydrochloride; the other ascending doses from 100 mg to 600 mg. The primary outcome was the rate of methadone dose reduction over six months.

The sponsor reported preliminary findings in January 2025, drawn from the initial 100 mg phase: all participants reduced their daily methadone dose by 50% for one week after dosing; withdrawal scores rose slightly at 12 hours but stayed below clinically significant thresholds; there were no serious adverse events, with fatigue and dizziness most common; and one participant was excluded for significant QT prolongation.

How much weight this carries. It is a genuine randomised, blinded trial, which almost no ibogaine research is. It is also n = 20, single-centre, comparing two active doses rather than drug against placebo, and it measured a short-term dose reduction, not abstinence. No peer-reviewed report of the full results is currently indexed in PubMed or Europe PMC.

What else exists is thin. A 2017 case report described a 47-year-old woman, seventeen years on methadone, who used low, repeated, escalating ibogaine doses over six weeks and remained off maintenance at twelve months with no clinically significant QTc change — n = 1, self-administered. The larger open-label cohorts (Mash, n = 191; Brown and Alper, n = 30; Noller, n = 14, including one death) and Alper's foundational 1999 series of 33 cases all enrolled people dependent on short-acting opioids; in Mash's programme participants were switched to morphine sulfate before dosing. A Phase 1/2a industry trial (NCT05029401, 116 enrolled) completed in January 2024 without published efficacy results.

This is the question behind most searches for how long to switch from methadone before ibogaine, and it has no regulator-validated answer.

The Clinical Guidelines for Ibogaine-Assisted Detoxification published by the Global Ibogaine Therapy Alliance are the most widely referenced non-regulatory protocol. For methadone they specify:

• People on methadone should first be transitioned to a short-acting opioid, preferably morphine sulfate, under medical supervision
• Residual methadone should be no more than about 2 mg before ibogaine is given
• Assuming a 24-hour half-life, someone on 100 mg/day would clear to that level by roughly day 7
• Assuming a conservative 48-hour half-life, the same patient needs approximately 14 days
• The switch must be gradual; abrupt high-dose substitution causes over-sedation and raises tolerance before treatment even begins

Two rationales drive the requirement. First, ibogaine potentiates opioid analgesia, so dosing while methadone remains in circulation creates an overdose risk. Second, that same potentiation masks withdrawal during the session; as it subsides, patients may experience residual withdrawal and protracted symptoms that the treatment was supposed to have resolved.

Three caveats belong alongside the protocol:

1. These are consensus harm-reduction guidelines from an advocacy body — not regulatory guidance, and not validated in any controlled trial. The gap between seven and fourteen days reflects genuine uncertainty
2. The transition itself is a risk period: a stable patient is deliberately moved onto a short-acting full agonist, with the instability that implies
3. Methadone's half-life varies roughly sevenfold between individuals, so any fixed clearance schedule is an approximation applied to a population with wide pharmacokinetic spread

Because ibogaine is Schedule I in the United States, people seeking it travel to countries where it is unscheduled or tolerated — most commonly Mexico, and also Costa Rica and Portugal. Oversight varies widely, no binding accreditation standard exists, and none of these programmes is an approved treatment for methadone discontinuation anywhere in the world.

Minimum screening for any responsibly run programme includes:

• 12-lead ECG with QTc measurement, and cardiology review of any abnormality
• Serum potassium and magnesium, corrected before dosing
• Liver and renal function, full blood count, and pregnancy testing
• Complete medication reconciliation, screening for QT-prolonging and serotonergic drugs
• CYP2D6 genotyping where available, to identify poor metabolisers with prolonged exposure

For methadone patients specifically, several additional steps are not optional:

• A documented, supervised transition off methadone with laboratory confirmation of elimination
• Baseline ECG interpreted against the patient's own methadone-era readings, since many arrive with an already-prolonged QTc
• Benzodiazepine and alcohol assessment — unmanaged sedative withdrawal is independently dangerous and appears in the fatality literature
• Overdose counselling and take-home naloxone, because tolerance is reset
• A concrete aftercare plan agreed before travel, not improvised afterward

The acute course involves several hours of intense psychoactive effects followed by an extended recovery, commonly with profound ataxia, nausea, vomiting, and inability to stand unassisted for many hours. Continuous cardiac telemetry is standard practice. The monitoring window matters: in the reviewed fatality series, deaths occurred anywhere from 1.5 to 76 hours after ingestion, which is longer than many programmes observe patients.

Ibogaine's safety profile is dominated by cardiac electrophysiology. For methadone patients the problem compounds, because methadone is itself a potassium-channel blocker.

The mechanism. Ibogaine and noribogaine block hERG potassium channels, reducing repolarisation reserve and creating substrate for torsades de pointes. Methadone inhibits the same rapid delayed-rectifier current, which is why it carries its own QT warning.

How common that already is. A systematic review and meta-analysis by Paknahad and colleagues (Medicine, 2025) pooled 22 observational studies of roughly 10,000 people in methadone maintenance and found QTc prolongation in 34% (95% CI 24–43%) and torsades de pointes in about 2%, rising to 6% when pharmacovigilance reports were included. Two-thirds of studies showed a dose–response relationship, including an increase of roughly 28 ms moving from 50 mg to 150 mg or more daily. A QTc at or above 500 ms carried a roughly fourfold increase in sudden cardiac death risk.

The practical implication: a third of people presenting from methadone maintenance may already have a prolonged QTc before any ibogaine is given. In the one randomised trial, a participant was excluded for exactly this.

The outcomes. Alper, Stajić and Gill (Journal of Forensic Sciences, 2012) reviewed 19 deaths temporally associated with ibogaine between 1990 and 2008. Advanced pre-existing conditions — mainly cardiovascular — or commonly abused substances explained or contributed to death in 12 of the 14 cases with adequate postmortem data.

Risks specific to leaving methadone, additive to the cardiac risk rather than alternatives to it:

• Loss of documented mortality protection — roughly six times higher all-cause mortality in the four weeks after stopping agonist treatment
• Tolerance reset and overdose; in a fentanyl-dominant supply, a previously tolerated dose can be fatal
• The pre-treatment switch to a short-acting agonist, itself a destabilising period
• QT-prolonging psychiatric medications common in this population — SSRIs, trazodone, quetiapine, hydroxyzine
• Benzodiazepine co-dependence, a contraindication until independently stabilised

Generally accepted absolute contraindications include long QT syndrome, structural heart disease, heart failure, recent myocardial infarction, uncorrected electrolyte abnormality, significant hepatic or renal impairment, pregnancy, active psychosis or bipolar I disorder, and concurrent MAOI or strongly serotonergic medication.

Legal status. Ibogaine is a Schedule I controlled substance under the US Controlled Substances Act — high abuse potential, no currently accepted medical use, no accepted safety under medical supervision. It is not approved for opioid use disorder or for methadone discontinuation in any country.

The policy landscape is moving. Texas Senate Bill 2308 authorises state matching funds for an FDA-approved clinical trial run by a public university with pharmaceutical and hospital partners, targeting opioid use disorder, depression and PTSD. Several other states have introduced research legislation. None of this changes federal scheduling, and none of it is evidence of efficacy.

What would actually advance this question:

• A placebo-controlled trial in methadone-maintained patients. The existing randomised study compared two active doses and reported a one-week dose reduction; nobody has shown ibogaine beats placebo here
• Longer follow-up with biologically confirmed outcomes. Dose reduction at one week is not abstinence at one year
• Replication outside a single centre, and full peer-reviewed publication of the trial already completed
• Prospective cardiac stratification for a population in which a third already have QTc prolongation, including whether prior methadone exposure alters ibogaine's arrhythmic risk
• Comparative data against slow, stepped tapering, which has the best conventional evidence and better outcomes than most people assume when run over a year or more
• Mortality as a pre-specified endpoint. Given the sixfold post-cessation mortality signal, any programme that ends maintenance must count deaths, not only successes

The honest bottom line. Ibogaine has one small completed randomised trial in methadone-maintained patients suggesting short-term tolerance reduction, one case report, and a larger body of open-label work in people using short-acting opioids. It has never been shown to produce durable abstinence from methadone, and it carries a documented risk of fatal arrhythmia in a population already predisposed to it. Methadone maintenance has among the strongest mortality evidence in addiction medicine. The burden of proof here is high and has not been met.

---

This page is educational information, not medical advice. It does not recommend ibogaine or endorse any clinic. Decisions about starting, continuing, tapering, or stopping methadone should be made with a prescribing clinician. Stopping opioid agonist treatment abruptly or without a plan substantially increases the risk of overdose death.